Tian-Cai Liu1, Mei-Jun Chen1, Zhi-Qi Ren1, Jing-Yuan Hou1, Guan-Feng Lin1, Ying-Song Wu2. 1. Institute of Antibody Engineering, School of Biotechnology, Southern Medical University, Guangzhou 510515, PR China. 2. Institute of Antibody Engineering, School of Biotechnology, Southern Medical University, Guangzhou 510515, PR China. Electronic address: wg@smu.edu.cn.
Abstract
OBJECTIVES: Diabetes mellitus is a chronic disease affecting millions of people globally and resulting in significant death rates each year. A fast, inexpensive alternative to traditional testing and monitoring techniques is desirable, since secretion of insulin and C-peptide is impaired in diabetes mellitus. DESIGN AND METHODS: A highly sensitive immunoassay was developed for the simultaneous measurement of C-peptide and insulin levels in human serum, utilizing dual-label time-resolved fluoroimmunoassay (TRFIA) and magnetic particle technologies. This assay was characteristic for a single-step sandwich-type immunoassay, wherein antibody-coated magnetic particles were used as the solid phase and Eu(3+) and Sm(3+) chelate labels were used for detection. RESULTS: Antibody-coated magnetic particles in a TRFIA format performed well in addressing a number of quantitative needs. CONCLUSIONS: The results of this assay correlated well with commercial chemiluminescence assays and provided a number a advantages, including reduced sample volume, reduced reagent and personnel costs and reduced assay time, while maintaining the required clinical sensitivity.
OBJECTIVES:Diabetes mellitus is a chronic disease affecting millions of people globally and resulting in significant death rates each year. A fast, inexpensive alternative to traditional testing and monitoring techniques is desirable, since secretion of insulin and C-peptide is impaired in diabetes mellitus. DESIGN AND METHODS: A highly sensitive immunoassay was developed for the simultaneous measurement of C-peptide and insulin levels in human serum, utilizing dual-label time-resolved fluoroimmunoassay (TRFIA) and magnetic particle technologies. This assay was characteristic for a single-step sandwich-type immunoassay, wherein antibody-coated magnetic particles were used as the solid phase and Eu(3+) and Sm(3+) chelate labels were used for detection. RESULTS: Antibody-coated magnetic particles in a TRFIA format performed well in addressing a number of quantitative needs. CONCLUSIONS: The results of this assay correlated well with commercial chemiluminescence assays and provided a number a advantages, including reduced sample volume, reduced reagent and personnel costs and reduced assay time, while maintaining the required clinical sensitivity.